Willingness to use and preferences for long‐acting injectable PrEP among sexual and gender minority...
Willingness to use and preferences for long‐acting injectable PrEP among sexual and gender minority populations in the southern United States, 2021–2022: cross‐sectional study
About this item
Full title
Author / Creator
Publisher
Switzerland: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
Switzerland: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Introduction
Long‐acting injectable (LAI) pre‐exposure prophylaxis (PrEP) for HIV prevention was approved by the U.S. Food and Drug Administration in 2021. LAI PrEP is more effective than oral PrEP. However, it is not clear whether the groups most at risk of HIV in the United States will use LAI PrEP. Willingness to use LAI PrEP and preference f...
Alternative Titles
Full title
Willingness to use and preferences for long‐acting injectable PrEP among sexual and gender minority populations in the southern United States, 2021–2022: cross‐sectional study
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_1e336d11fb7b48c38d56179e5e468ae8
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_1e336d11fb7b48c38d56179e5e468ae8
Other Identifiers
ISSN
1758-2652
E-ISSN
1758-2652
DOI
10.1002/jia2.26077
